LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
10 hedge funds and large institutions have $4.89M invested in LakeShore Biopharma in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0.2% less ownership
Funds ownership: 1.2% → 1.01% (-0.2%)
17% less funds holding
Funds holding: 12 → 10 (-2)
45% less capital invested
Capital invested by funds: $8.93M → $4.89M (-$4.04M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$751K |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$290K |
| 3 |
SLM
Snow Lake Management
Menlo Park,
California
|
-$286K |
| 4 |
CAC
Cowen and Company
New York
|
-$9.88K |
| 5 |
Barclays
London,
United Kingdom
|
-$4.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $1.65M | -$751K | -130,511 | -29% |
|
|
2
Fidelity International
Hamilton,
Bermuda
| $1.18M | -$290K | -50,334 | -19% |
|
|
VAM
3
Valliance Asset Management
Central,
Hong Kong
| $821K | – | – | – |
|
4
Fidelity Investments
Boston,
Massachusetts
| $627K | – | – | – |
|
|
HA
5
HHLR Advisors
Grand Cayman,
Cayman Islands
| $404K | – | – | – |
|
|
SCM
6
Superstring Capital Management
New York
| $166K | +$177K | +30,792 | New |
|
|
7
Citadel Advisors
Miami,
Florida
| $23.1K | +$24.7K | +4,286 | New |
|
8
Geode Capital Management
Boston,
Massachusetts
| $7.32K | – | – | – |
|
|
PAM
9
Pinpoint Asset Management
Hong Kong
| $1.9K | – | – | – |
|
|
WAM
10
Wolverine Asset Management
Chicago,
Illinois
| $254 | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $2 | -$127 | -22 | Closed |
|
|
SLM
12
Snow Lake Management
Menlo Park,
California
| – | -$286K | -35,715 | Closed |
|
|
CAC
13
Cowen and Company
New York
| – | -$9.88K | -1,236 | Closed |
|
|
14
Barclays
London,
United Kingdom
| – | -$4.55K | -569 | Closed |
|
LSB Hedge Fund Activity: Q4 2023 in Review
10 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q4 2023, worth a combined $4.89M — down 45% from $8.93M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSB and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $24.7K. The largest seller was OrbiMed, cutting an estimated $751K.
- 10 institutional investors held LakeShore Biopharma (LSB) as of Q4 2023, down from 12 in Q3 2023.
- Funds reported $4.89M of LakeShore Biopharma stock for Q4 2023, down 45% quarter-over-quarter.
- 2 funds opened new LakeShore Biopharma positions in Q4 2023 and 4 closed out, a net change of -2 holders.
- The largest LakeShore Biopharma buyer in Q4 2023 was Citadel Advisors, an estimated $24.7K added.
- The largest LakeShore Biopharma seller in Q4 2023 was OrbiMed, an estimated $751K sold.
Based on aggregated 13F filings for Q4 2023.